United States Biopsy Market is expected to reach US$ 21.40 Billion by 2028, according to the publisher. A biopsy is a medical procedure in which a small tissue sample is removed from the body for examination, typically to diagnose or monitor a disease or condition. Biopsies in the United States are commonly performed by healthcare professionals such as pathologists, surgeons, or radiologists. The biopsy market in the United States is a growing due to the increasing demand for early and accurate diagnoses of various medical conditions.The United States Biopsy Industry was US$ 16.43 Billion in 2022
The market includes a variety of biopsy products and services, including biopsy needles, biopsy forceps, imaging guidance systems, and laboratory services. In recent years, the market has seen growth in the use of minimally invasive biopsy techniques, such as fine needle aspiration and core needle biopsy, as well as advances in imaging technologies, such as ultrasound and magnetic resonance imaging that help guide biopsy procedures. Additionally, the aging population and increasing rates of chronic diseases are contributing to the growth of the biopsy market in the United States.
USA Biopsy Market will grow with a 4.50% CAGR during the Forecast Period
Despite the growth of the biopsy market in the United States, a few challenges need to be addressed. One of the significant challenges is the need for more skilled professionals, such as pathologists, who analyze the biopsy samples and diagnose. Another challenge is the high cost of biopsy procedures, which can be a barrier for some patients, especially those without insurance. The United States Biopsy Industry was US$ 16.43 Billion in 2022.Breast Cancer is the most prevalent cancer on the list, with 290,560 new cases anticipated in the U.S in 2022
In the United States, biopsy procedures are commonly performed to diagnose or monitor different types of cancer. Some of the most common cancers for which biopsy procedures are performed include Breast Cancer, prostate, lung, liver, thyroid, kidney, colorectal, and melanoma. The most common type of biopsy procedure performed for breast cancer is a fine needle aspiration or core needle biopsy. A biopsy is often used to confirm a diagnosis of breast cancer. The breast cancer biopsy market in the United States is a significant and growing market due to the increasing incidence of breast cancer and advancements in biopsy techniques. According to our reports, the U.S. breast cancer biopsy market is expected to grow significantly in the coming years. The market growth can be attributed to increasing demand for early diagnosis, raising awareness about breast cancer, and advancements in biopsy technology.Another factor contributing to the growth of the biopsy market in the United States is the aging population and the increasing incidence of chronic diseases. As people age, they are more likely to develop chronic conditions, such as cancer, which require an early and accurate diagnosis. The increasing incidence of cancer has led to a higher demand for biopsy procedures, which has driven the biopsy market growth.
Key Companies & Market Insights
The biopsy market in the United States is highly competitive, with many players offering various products and services. Some of the leading players in the market include Becton, Dickinson & Company, Braun Melsungen AG, Cardinal Health, Inc., Medtronic Plc., Hologic, Inc., Bio-Rad Laboratories Inc, Quest Diagnostics, Thermo Fisher Scientific Inc, Roche Diagnostics and Myriad Genetics Inc. These companies are investing heavily in research and development to develop new biopsy technologies and products to meet the growing demand. They are also working to improve the accuracy and precision of biopsy procedures and reduce the risk of complications.For instance, Epic Biosciences announced the availability of a multi-analyte liquid biopsy for metastatic breast cancer in January 2022. DefineMBC from the company offers both cell-free and cell-based analyses.
In conclusion, the biopsy market in the United States is a growing industry driven by the increasing demand for early and accurate diagnoses of various medical conditions. With the advancements in technology and the rising incidence of chronic diseases, the market is expected to grow in the coming years. However, companies in the biopsy market will need to address the challenges of a shortage of skilled professionals and high costs to continue to grow and succeed.
The report titled “United States Biopsy Market, Volume & Forecast by Segments (Breast Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Thyroid Cancer, Kidney Cancer, Colorectal Cancer and Melanoma Cancer) Cancer, Companies (Becton, Dickinson & Company, Braun Melsungen AG, Cardinal Health, Inc., Medtronic Plc., Hologic, Inc., Bio-Rad Laboratories Inc, Quest Diagnostics, Thermo Fisher Scientific Inc, Roche Diagnostics and Myriad Genetics Inc)” provides a complete analysis of the United States Biopsy Market and Volume.
United States Biopsy Volume Insights - In this report, we have Fragmented Cancer by Biopsy Volume into 8 parts
1. Breast Cancer2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Kidney Cancer
7. Colorectal Cancer
8. Melanoma Cancer
United States Biopsy Market Insights: In this report, we have Categorized the Biopsy Market into 8 parts by Cancer Type
1. Breast Cancer2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Kidney Cancer
7. Colorectal Cancer
8. Melanoma Cancer
Company Insights:
- Overview
- Company Initiatives
- Sales Analysis
Key Companies Covered in the Report:
1. Becton, Dickinson & Company2. Braun Melsungen AG
3. Cardinal Health, Inc.
4. Medtronic Plc.
5. Hologic, Inc.
6. Bio-Rad Laboratories Inc
7. Quest Diagnostics
8. Thermo Fisher Scientific Inc
9. Roche Diagnostics
10. Myriad Genetics Inc
Table of Contents
1. Introduction2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Biopsy Devices: Competitive Assessment
5.1 Assessment by Product Type
5.1.1 Core Biopsy Devices
5.1.2 Aspiration Biopsy Needles
5.1.3 Vacuum Assisted Biopsy Devices
5.2 Assessment by Technique
5.2.1 Ultrasound-guided Biopsy
5.2.2 Stereotactic-guided Biopsy
5.2.3 MRI-guided Biopsy
6. United States Cancer Cases
6.1 Total Number of Cancer Cases
6.1.1 Breast Cancer
6.1.2 Prostate Cancer
6.1.3 Lung Cancer
6.1.4 Liver Cancer
6.1.5 Thyroid Cancer
6.1.6 Kidney Cancer
6.1.7 Colorectal Cancer
6.1.8 Melanoma Cancer
6.2 Cancer Cases by Gender
6.3 Cancer Cases by Age Group
7. United States Biopsy Market & Volume Analysis
7.1 Market
7.2 Volume
8. Market & Volume Share - United States Biopsy Analysis
8.1 Market Share
8.2 Volume Share
9. Segment - United States Biopsy Market
9.1 Prostate Cancer Biopsy
9.1.1 Market
9.1.2 Volume
9.2 Breast Cancer Biopsy
9.2.1 Market
9.2.2 Volume
9.3 Lung Cancer Biopsy
9.3.1 Market
9.3.2 Volume
9.4 Liver Cancer Biopsy
9.4.1 Market
9.4.2 Volume
9.5 Thyroid Cancer Biopsy
9.5.1 Market
9.5.2 Volume
9.6 Kidney Cancer Biopsy
9.6.1 Market
9.6.2 Volume
9.7 Colon & Rectum Cancer Biopsy
9.7.1 Market
9.7.2 Volume
9.8 Melanoma Skin Cancer Biopsy
9.8.1 Market
9.8.2 Volume
10. Porters Five Forces
10.1 Bargaining Power of Buyers
10.2 Bargaining Power of Suppliers
10.3 Degree of Competition
10.4 Threat of New Entrants
10.5 Threat of Substitutes
11. Merger & Acquisition
12. Company Analysis
12.1 Becton, Dickinson & Company
12.1.1 Overview
12.1.2 Recent Developments
12.1.3 Revenue
12.2 B. Braun Melsungen AG (Germany)
12.2.1 Overview
12.2.2 Recent Developments
12.2.3 Revenue
12.3 Cardinal Health, Inc.
12.3.1 Overview
12.3.2 Recent Developments
12.3.3 Revenue
12.4 Medtronic Plc.
12.4.1 Overview
12.4.2 Recent Developments
12.4.3 Revenue
12.5 Hologic, Inc.
12.5.1 Overview
12.5.2 Recent Developments
12.5.3 Revenue
12.6 Bio-Rad Laboratories Inc
12.6.1 Overview
12.6.2 Recent Developments
12.6.3 Revenue
12.7 Quest Diagnostics
12.7.1 Overview
12.7.2 Recent Developments
12.7.3 Revenue
12.8 Thermo Fisher Scientific Inc
12.8.1 Overview
12.8.2 Recent Developments
12.8.3 Revenue
12.9 Roche Diagnostics
12.9.1 Overview
12.9.2 Recent Developments
12.9.3 Revenue
12.10 Myriad Genetics Inc
12.10.1 Overview
12.10.2 Recent Developments
12.10.3 Revenue
List of Figures:
Figure 01: United States - Biopsy Market (Billion US$), 2018 - 2022
Figure 02: United States - Forecast for Biopsy Market (Billion US$), 2023 - 2028
Figure 03: United States - Biopsy Volume (Thousand), 2018 - 2022
Figure 04: United States - Forecast for Biopsy Volume (Thousand), 2023 - 2028
Figure 05: United States - Prostate Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 06: United States - Forecast for Prostate Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 07: United States - Prostate Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 08: United States - Forecast for Prostate Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 09: United States - Breast Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 10: United States - Forecast for Breast Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 11: United States - Breast Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 12: United States - Forecast for Breast Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 13: United States - Lung Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 14: United States - Forecast for Lung Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 15: United States - Lung Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 16: United States - Forecast for Lung Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 17: United States - Liver Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 18: United States - Forecast for Liver Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 19: United States - Liver Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 20: United States - Forecast for Liver Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 21: United States - Thyroid Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 22: United States - Forecast for Thyroid Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 23: United States - Thyroid Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 24: United States - Forecast for Thyroid Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 25: United States - Kidney Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 26: United States - Forecast for Kidney Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 27: United States - Kidney Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 28: United States - Forecast for Kidney Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 29: United States - Colon & Rectum Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 30: United States - Forecast for Colon & Rectum Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 31: United States - Colon & Rectum Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 32: United States - Forecast for Colon & Rectum Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 33: United States - Melanoma Skin Cancer Biopsy Market (Million US$), 2018 - 2022
Figure 34: United States - Forecast for Melanoma Skin Cancer Biopsy Market (Million US$), 2023 - 2028
Figure 35: United States - Melanoma Skin Cancer Biopsy Volume (Thousand), 2018 - 2022
Figure 36: United States - Forecast for Melanoma Skin Cancer Biopsy Volume (Thousand), 2023 - 2028
Figure 37: Becton, Dickinson & Company - Global Revenue (Billion US$), 2018 - 2022
Figure 38: Becton, Dickinson & Company - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 39: B. Braun Melsungen AG (Germany) - Global Revenue (Billion US$), 2018 - 2022
Figure 40: B. Braun Melsungen AG (Germany) - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 41: Cardinal Health, Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 42: Cardinal Health, Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 43: Medtronic Plc. - Global Revenue (Billion US$), 2018 - 2022
Figure 44: Medtronic Plc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 45: Hologic, Inc. - Global Revenue (Million US$), 2018 - 2022
Figure 46: Hologic, Inc. - Forecast for Global Revenue (Million US$), 2023 - 2028
Figure 47: Bio-Rad Laboratories Inc - Global Revenue (Million US$), 2018 - 2022
Figure 48: Bio-Rad Laboratories Inc - Forecast for Global Revenue (Million US$), 2023 - 2028
Figure 49: Quest Diagnostics - Global Revenue (Billion US$), 2018 - 2022
Figure 50: Quest Diagnostics - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 51: Thermo Fisher Scientific Inc - Global Revenue (Billion US$), 2018 - 2022
Figure 52: Thermo Fisher Scientific Inc - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 53: Roche Diagnostics - Global Revenue (Billion US$), 2018 - 2022
Figure 54: Roche Diagnostics - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 55: Myriad Genetics Inc - Global Revenue (Million US$), 2018 - 2022
Figure 56: Myriad Genetics Inc - Forecast for Global Revenue (Million US$), 2023 - 2028
List of Tables:
Table 1: United States - Biopsy Market Share by Cancer Type (Percent), 2018 - 2022
Table 2: United States - Forecast for Biopsy Market Share by Cancer Type (Percent), 2023 - 2028
Table 3: United States - Biopsy Volume Share by Cancer Type (Percent), 2018 - 2022
Table 4: United States - Forecast for Biopsy Volume Share by Cancer Type (Percent), 2023 - 2028
Companies Mentioned
- Becton, Dickinson & Company
- Braun Melsungen AG
- Cardinal Health, Inc.
- Medtronic Plc.
- Hologic, Inc.
- Bio-Rad Laboratories Inc
- Quest Diagnostics
- Thermo Fisher Scientific Inc
- Roche Diagnostics
- Myriad Genetics Inc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | February 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 16.43 Billion |
| Forecasted Market Value ( USD | $ 21.4 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
